Assessing the effectiveness of upadacitinib for treating Crohn's disease in Japan

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the safety and effectiveness of upadacitinib in treating adolescents and adults with moderate to severe active Crohn's disease in Japan. Participants will receive upadacitinib as prescribed by their healthcare providers, and their disease activity and any adverse events will be monitored over a period of up to 64 weeks. Approximately 240 participants will be enrolled, and the study aims to reflect real-world clinical practices without imposing additional burdens on participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with moderately to severely active Crohn's disease (CD).
* Has been prescribed upadacitinib for CD as per most current local approved label after its approval for CD in Japan.
* Within 14 days from the commencement of upadacitinib induction treatment for CD at the participating institution.

Exclusion Criteria:

* Currently participating in another interventional clinical research.
* Participants for whom upadacitinib is contraindicated.
* Has been treated with upadacitinib for CD before and continue treatment with upadacitinib for CD at the participation to this study.

Where it's running

• Anjou Kousei Hospital /ID# 261872
  Anjo-shi, Aichi-ken, Japan Recruiting
• Handa City Hospital /ID# 270446
  Handa, Aichi-ken, Japan Recruiting
• Aichi Medical University Hospital /ID# 261871
  Nagakute, Aichi-ken, Japan Recruiting
• Masuko Memorial Hospital /ID# 267420
  Nagoya, Aichi-ken, Japan Recruiting
• Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital /ID# 276219
  Nagoya, Aichi-ken, Japan Recruiting
• Nagoya City University Hospital /ID# 275588
  Nagoya, Aichi-ken, Japan Recruiting

+54 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: AbbVie GK Clinical Trial Registration Desk
• Email: abbvie_jpn_info_clingov@abbvie.com
• Phone: +81-3-4577-1111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Second-line treatment with upadacitinib or risankizumab for adults with Crohn's disease

  This project will test how well upadacitinib or risankizumab work as second-line treatments for adults with moderate-to-severe Crohn's disease who previously used a TNF inhibitor.

  Recruiting at 25 sites AbbVie · Castellana Grotte, Bari and 24 other locations · NCT07073079

• Evaluating Upadacitinib for Inflammatory Bowel Disease

  This study is testing how well the oral medication Upadacitinib works for people in China with Inflammatory Bowel Disease who haven't responded to other treatments.

  Recruiting at 6 sites Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT06780683

• Assessing Upadacitinib Treatment in Adults with Inflammatory Bowel Disease in Belgium

  This study is testing how well the medication upadacitinib works and how safe it is for adults with moderate to severe ulcerative colitis and Crohn's disease in Belgium over three years.

  Recruiting at 11 sites AbbVie · Bonheiden, Antwerpen and 10 other locations · NCT06581042

• Combining vedolizumab and upadacitinib for treating Crohn's Disease

  This study is testing if combining two medications, vedolizumab and upadacitinib, can help adults with moderate to severe Crohn's Disease feel better compared to using vedolizumab alone.

  Recruiting at 8 sites Phase 3 Takeda · La Jolla, California and 137 other locations · NCT06227910

• Iron treatment for children and young adults with Crohn’s disease and iron deficiency anemia

  This study tests how different iron treatment approaches work for kids and young adults with Crohn’s disease and iron deficiency anemia.

  Recruiting Phase 4 Weill Medical College of Cornell University · New York, New York · NCT07925450

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.